HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and raised the price target from $19 to $20.
August 05, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Travere Therapeutics and raised the price target from $19 to $20.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and could lead to a short-term increase in TVTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100